Terns Pharmaceuticals Is A Clinical Stage Biopharmaceutical Company Based In Foster Citycaliforniafounded In 2018The Company Is Dedicated To Developing Innovative Therapies For Serious Diseasesfocusing On Oncologyobesityand Chronic Liver Diseasesincluding Non Alcoholic Steatohepatitisnashand Chronic Myeloid Leukemiacml Terns Has Raised A Total Of $378 Million In Fundingsupporting Its Research And Development Efforts Through 2028 The Company S Pipeline Includes Several Small Molecule Candidatestern 101 Is An Fxr Agonist For Nash That Has Shown Promising Results In Clinical Trialstern 601 Is A Once Daily Oral Glp 1R Agonist For Obesitywith Positive Phase 1 Trial Results And Plans For A Phase 2 Trial In 2025Additionallytern 201 Is An Oral Vap 1 Inhibitor For Nash And Other Chronic Diseaseswhile Tern 701 Is A Candidate For Cml That Achieved Its Primary Endpoint In A Phase 1 Clinical Trial In 2024Terns Pharmaceuticals Is Committed To Advancing Medical Science Through Its Innovative Drug Development And Clinical Trials
